RMC-6236 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 3 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of RMC-6236’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for RMC-6236 is expected to reach an annual total of $204 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RMC-6236 is under development for the treatment of solid tumor, colorectal cancer, pancreatic ductal adenocarcinoma cancer and non-small cell lung cancer. It is administered through oral route. The drug candidate is a RAS-selective, tri-complex inhibitor. It acts by targeting the GTP bound form of KRAS (G12V, G12D, G13C, G13D, Q61H), NRAS (Q61X) and HRAS mutants.
Revolution Medicines Overview
Revolution Medicines is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
The company reported revenues of (US Dollars) US$35.4 million for the fiscal year ended December 2022 (FY2022), an increase of 20.4% over FY2021. The operating loss of the company was US$258.3 million in FY2022, compared to an operating loss of US$188 million in FY2021. The net loss of the company was US$248.7 million in FY2022, compared to a net loss of US$187.1 million in FY2021.
For a complete picture of RMC-6236’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.